TY - JOUR T1 - Invasive airway “Intubation” in COVID-19 patients :statistics, causes and recommendations JF - medRxiv DO - 10.1101/2021.04.08.21254439 SP - 2021.04.08.21254439 AU - Mostafa Mohammadi AU - Alireza Khafaee Pour Khamseh AU - Hesam Aldin Varpaei Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/04/11/2021.04.08.21254439.abstract N2 - Background Severe COVID-19 disease could induce acute respiratory distress which is characterized by tachypnea, hypoxia, and dyspnea. Intubation and mechanical ventilation are a strategic treatment of COVID-19 distress or hypoxia.Methods We searched PubMed, Embase, and Scopus databases through April 1, 2021, to identify relevant randomized control trials, observational studies, and case series.Results 24 studies were included in this review. Studies were conducted in the USA, China, Spain, South Korea, Italy, Iran, and Brazil. Most patients were intubated in the intensive care unit. Rapid sequence induction was mostly used for intubation. ROX index might be utilized for the predictor of the necessity of intubation in COVID-19 patients. According to the previous studies the rate of intubation reported 5 to 88%. It was revealed that 1.4 - 44.5% of patients might be extubated. Yet obesity and age (elderly) are the only risk factors of delayed or difficult extubation.Discussion and conclusion Acute respiratory distress in COVID-19 patients could require endotracheal intubation and mechanical ventilation. Severe respiratory distress, loss of consciousness, and hypoxia were the most important reasons for intubation. Also, increased levels of ferritin, d-dimer, and lipase in common with hypoxia are correlated with intubation and ICU admission Mortality following intubation is reported to be 15 to 36%. Awake-prone positioning in comparison to high-flow nasal oxygen therapy did not reduce the risk of intubation and mechanical ventilation. There was no association between intubation timing and mortality of infected patients. noninvasive ventilation may have survival benefits.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis study approved by internal ethical committee of critical care, Imam Khomeini hospital complex. Ethic code: IR.TUMS.VCR.REC.1399.389Funding StatementThis study received no funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the internal ethical committee of critical care, Imam Khomeini hospital complex. Ethics code number IR.TUMS.VCR.REC.1399.389.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data were collected from PubMed, Embase, and Scopus and google scholar databases.All data (articles which mentioned in references) are available online. ER -